Myers R E, Johnston M, Pritchard K, Levine M, Oliver T
Department of Oncology, Credit Valley Hospital, Mississauga, Ont.
CMAJ. 2001 May 15;164(10):1439-44.
Breast cancer develops in over 7000 women each year in Ontario. These patients will all undergo some staging work-up at diagnosis. The Breast Cancer Disease Site Group of the Cancer Care Ontario Practice Guidelines Initiative reviewed the evidence and indications for routine bone scanning, liver ultrasonography and chest radiography in asymptomatic women who have undergone surgery for breast cancer.
A systematic review of the published literature was combined with a consensus interpretation of the evidence in the context of conventional practice.
There were 11 studies of bone scanning reported between 1972 and 1980, involving a total of 1307 women; bone scans detected skeletal metastases in 6.8% of those with stage I breast cancer, 8.8% with stage II and 24.5% with stage III. A total of 5407 women participated in 9 studies of bone scanning reported between 1985 and 1995; in these studies, bone scans detected skeletal metastases in only 0.5% of women with stage I disease, 2.4% with stage II and 8.3% with stage III. Among 1625 women in 4 studies of liver ultrasonography reported between 1988 and 1993, hepatic metastases were detected in 0% of patients with stage I disease, 0.4% with stage II and 2.0% with stage III. Among 3884 patients in 2 studies of chest radiography published in 1988 and 1991, lung metastases were detected in 0.1% of those with stage I, 0.2% with stage II and 1.7% with stage III. False-positive rates ranged from 10% to 22% for bone scanning, 33% to 66% for liver ultrasonography and 0% to 23% for chest radiography. The false-negative rate for bone scanning was about 10%.
The following recommendations apply to women with newly diagnosed breast cancer who have undergone surgical resection and who have no symptoms, physical signs or biochemical evidence of metastases. Routine bone scanning, liver ultrasonography and chest radiography are not indicated before surgery. In women with intraductal and pathological stage I tumours, routine bone scanning, liver ultrasonography and chest radiography are not indicated as part of baseline staging. In women who have pathological stage II tumours, a postoperative bone scan is recommended as part of baseline staging. Routine liver ultrasonography and chest radiography are not indicated in this group but could be considered for patients with 4 or more positive lymph nodes. In women with pathological stage III tumours, bone scanning, liver ultrasonography and chest radiography are recommended postoperatively as part of baseline staging. In women for whom treatment options are restricted to tamoxifen or hormone therapy, or for whom no further treatment is indicated because of age or other factors, routine bone scanning, liver ultrasonography and chest radiography are not indicated as part of baseline staging.
安大略省每年有超过7000名女性患乳腺癌。这些患者在确诊时都要接受一些分期检查。安大略癌症护理实践指南倡议组织的乳腺癌疾病部位小组审查了无症状乳腺癌手术患者常规骨扫描、肝脏超声检查和胸部X光检查的证据及适应症。
对已发表文献进行系统回顾,并结合传统实践背景下对证据的共识解读。
1972年至1980年期间报告了11项关于骨扫描的研究,共涉及1307名女性;骨扫描在I期乳腺癌患者中检测到骨转移的比例为6.8%,II期为8.8%,III期为24.5%。1985年至1995年期间报告的9项骨扫描研究共有5407名女性参与;在这些研究中,骨扫描在I期疾病女性中仅检测到0.5%的骨转移,II期为2.4%,III期为8.3%。在1988年至1993年报告的4项肝脏超声检查研究中的1625名女性中,I期疾病患者未检测到肝转移,II期为0.4%,III期为2.0%。在1988年和1991年发表的2项胸部X光检查研究中的3884名患者中,I期患者检测到肺转移的比例为0.1%,II期为0.2%,III期为1.7%。骨扫描的假阳性率为10%至22%,肝脏超声检查为33%至66%,胸部X光检查为0%至23%。骨扫描的假阴性率约为10%。
以下建议适用于新诊断为乳腺癌且已接受手术切除、无症状、无体征或无转移生化证据的女性。术前不建议进行常规骨扫描、肝脏超声检查和胸部X光检查。对于导管内癌和病理I期肿瘤的女性,不建议将常规骨扫描、肝脏超声检查和胸部X光检查作为基线分期的一部分。对于病理II期肿瘤的女性,建议术后进行骨扫描作为基线分期的一部分。该组不建议常规进行肝脏超声检查和胸部X光检查,但对于有4个或更多阳性淋巴结的患者可考虑进行。对于病理III期肿瘤的女性,建议术后进行骨扫描、肝脏超声检查和胸部X光检查作为基线分期的一部分。对于治疗选择仅限于他莫昔芬或激素治疗,或因年龄或其他因素无需进一步治疗的女性,不建议将常规骨扫描、肝脏超声检查和胸部X光检查作为基线分期的一部分。